human
activ
lymphocyt
express
dass
ii
molecul
abl
present
complex
antigen
bind
surfac
receptor
thu
captur
intern
process
class
ii
major
histocompat
complex
process
pathway
use
antigenpres
cell
system
identifi
viral
receptor
use
hepat
b
viru
hbv
enter
cell
well
sequenc
hb
envelop
antigen
hbenvag
involv
interact
result
show
clone
process
present
hbenvag
class
iirestrict
cytotox
lymphocyt
transferrin
receptor
tfr
involv
effici
hbenvag
uptak
cell
moreov
provid
evid
hbenvag
sequenc
interact
cell
surfac
contain
within
region
sinc
tfr
also
express
hepatocyt
might
repres
portal
cellular
entri
hbv
infect
system
antigen
present
cell
may
serv
model
studi
lymphocyt
receptor
use
lymphocytotrop
virus
viral
protein
critic
bind
c
lymphocyt
recogn
exogen
antigen
peptid
bound
class
ii
mhc
molecul
express
surfac
apc
gener
repres
macrophag
dendrit
cell
b
cell
apc
intern
antigen
process
endosom
compart
expresson
membran
short
peptid
associ
class
ii
antigen
unlik
mous
cell
human
activ
lymphocyt
express
class
ii
molecul
shown
effici
present
denatur
antigen
peptid
requir
process
contrast
usual
fail
present
complex
antigen
need
process
unless
captur
antigen
membran
molecul
case
hiv
bind
monoval
receptor
manner
cell
effici
intern
antigen
process
class
ii
process
pathway
present
fragment
class
iirestrict
lymphocyt
specif
b
cell
via
ig
receptor
studi
demonstr
cell
clone
process
effici
present
hepat
b
envelop
antigen
hbenvag
class
iirestrict
ctl
turn
kill
present
cell
transferrin
receptor
tflk
involv
uptak
hbenvag
cell
moreov
identifi
hbenvag
region
involv
interact
reagent
plasmaderiv
nativ
hbenvag
sorin
saluggia
itali
contain
three
hepat
b
viru
hbv
envelop
protein
purifi
patient
chronic
hbv
infect
describ
antigen
prepar
contain
high
level
reactiv
shown
solid
phase
elisa
recombin
r
particl
contain
entir
surfac
protein
ofhbv
express
yeast
gift
p
j
kniskern
merck
sharp
dohm
research
laboratori
west
point
pa
delet
rhbenvag
form
contain
sequenc
domain
sequenc
domain
entir
domain
l
antigen
recombin
protein
display
antigen
determin
ena
part
work
appear
abstract
form
cell
biochera
code
region
recombin
protein
contain
region
express
yeast
kindli
donat
p
hanser
andj
petr
smithklin
biolog
rixensart
belgium
anoth
r
protein
express
cho
cell
provid
p
adamowicz
pasteur
vaccin
marnesla
coquett
franc
purifi
nativ
tetanu
toxoid
tt
obtain
institut
merieux
franc
synthet
peptid
analogu
region
purchas
american
peptid
compani
inc
santa
clara
ca
solubl
tf
purchas
calbiochembehr
corp
san
diego
ca
oktll
anticd
mab
purchas
ortho
pharmaceut
raritan
nj
fl
chain
mab
purchas
becton
dickinson
co
mountain
view
ca
mab
immunotech
marseil
franc
ts
clone
obtain
springer
mab
monomorph
determin
class
ag
purchas
cappel
laboratori
malvern
pa
mab
framework
determin
hladr
kindli
provid
p
giacomini
regina
elena
cancer
institut
rome
itali
antihladq
antihladp
purchas
becton
dickinson
co
purchas
antimhc
molecul
mab
use
dialysi
antigenspecif
cell
clone
antigenspecif
cell
clone
deriv
pbl
two
hb
vaccin
hevacb
pasteur
institut
pari
franc
recipi
whose
hladr
type
respect
briefli
pbl
plate
per
well
flatbottom
plate
falcon
labwar
oxnard
ca
presenc
gml
hbenvag
uml
hoffmannla
roch
basel
switzerland
ad
addit
grow
cultur
expand
cycl
restimul
antigen
plu
autolog
irradi
pbl
use
apc
cultur
chosen
capac
prolifer
respons
hbenvag
presenc
autolog
iapc
clone
limit
dilut
cell
per
well
pha
wellcom
dartford
uk
allogen
iapc
describ
tabl
show
antigen
specif
hla
restrict
select
clone
random
clone
obtain
clone
autolog
auogen
pbl
pha
hlaincompat
feeder
cell
ebvtransform
b
ebvb
cell
use
apc
cytotox
assay
scrlabel
ebvb
cell
clone
target
cell
puls
h
increas
concentr
entir
hbenvag
nativ
recombin
synthet
peptid
specif
cytotox
inhibit
experi
scrlabel
target
cell
incub
variou
mab
h
puls
either
antigen
peptid
experi
label
target
cell
treat
increas
concentr
tf
h
wash
puls
hbenvag
tt
anoth
h
viabil
target
cell
incub
mab
tf
target
cell
wash
cultur
x
h
antigenspecif
clone
et
ratio
roundbottom
plate
triplic
plate
centrifug
cellfre
supernat
collect
well
slcr
releas
evalu
gamma
counter
percent
specif
lysi
express
mean
triplic
determin
calcul
follow
experiment
releas
spontan
releas
maxim
releas
spontan
releas
usitf
usihbenvag
competit
bind
assay
purifi
human
tf
conjug
lzsi
solidphas
lactoperoxidas
system
new
england
nuclear
boston
bind
reaction
perform
x
polypropylen
tube
rpmi
contain
bsa
fraction
v
sigma
chemic
co
st
loui
mo
cell
concentr
x
cellsml
label
tf
ngml
unlabel
tf
differ
concentr
gml
experi
unlabel
tf
replac
differ
molecular
construct
hbenvag
ad
final
concentr
rang
gml
cell
incub
min
unbound
ligand
remov
passag
cell
densiti
cushion
describ
incub
aliquot
cell
suspens
layer
mixtur
dibutyl
phthalat
merck
darmstadt
germani
final
densiti
plastic
microfug
tube
centrifug
microfug
jouan
inc
winchest
va
rain
result
supernat
phthalat
oil
cushion
aspir
tip
vial
contain
cell
pellet
sever
scalpel
transfer
plastic
vial
radioact
measur
gamma
counter
ihbenvag
bind
perform
similar
experiment
condit
except
label
ligand
concentr
incub
cell
process
itf
bind
assay
hbenvag
fig
show
random
clone
use
apc
abl
present
hbenvag
class
iirestrict
specif
cytotox
clone
specif
ctl
use
experi
drsrestrict
clone
two
clone
recogn
synthet
peptid
mggwsskprkgmgtnlsvpnp
region
mqwnstafhqt
region
fflltriltipqsld
region
respect
tabl
lysi
present
cell
observ
significantli
lower
concentr
antigen
need
induc
compar
level
ebvb
kill
fig
cell
clone
select
present
hbenvag
isol
stimul
pha
use
auogen
ipbl
feeder
lack
appropri
class
ii
molecul
exclud
presenc
hlarestrict
convent
apc
clone
cytotox
lectindepend
cellmedi
cytotox
ldcc
assay
data
shown
experi
hbenvagspecif
clone
use
sourc
apc
abl
present
hbenvag
data
shown
case
exclud
presenc
autolog
convent
apc
clone
restimul
pha
use
allogen
ipbl
feeder
describ
hbenvag
present
cell
requir
process
sinc
cold
puls
result
drastic
inhibit
apc
capac
tabl
abil
restor
least
rain
incub
except
cell
incub
presenc
lysosomotrop
agent
chloroquin
sigma
chemic
co
inhibit
class
ii
endosom
process
pathway
tabl
contrast
recognit
peptid
presum
directli
bind
class
ii
molecul
without
process
affect
either
cold
chloroquin
treatment
defin
put
receptor
use
hbenvag
interact
cell
attempt
inhibit
specif
lysi
present
lymphocyt
treatment
variou
randomli
select
mab
lymphocyt
surfac
molecul
target
cell
incub
mab
h
either
antigen
puls
assum
block
hbenvag
uptak
lymphocyt
occur
mab
presum
hbenvag
receptor
ad
antigen
puls
clone
use
effector
result
show
mab
oktg
abl
inhibit
hbenvag
captur
cell
inde
mab
block
specif
lysi
ad
antigen
puls
tabl
moreov
also
block
lesser
degre
specif
lysi
ebvb
cell
ad
hbenvag
puls
tabl
contrast
antitfr
mab
inhibit
either
present
peptid
ebvb
cell
tabl
present
unrel
antigen
tt
ebvb
cell
ttspecif
line
tabl
inhibitori
effect
also
obtain
adhes
molecul
mab
tabl
mab
show
inhibitori
effect
hbenvag
puls
apc
also
ebvb
apc
slcrlabel
autolog
target
ebvb
cell
puls
gml
antigen
peptid
h
wash
incub
clone
cell
h
et
ratio
ctl
assay
peptid
pool
consist
mixtur
singl
peptid
gml
protein
respect
peptid
includ
sequenc
protein
protein
percent
specif
lysi
express
mean
triplic
determin
inhibit
present
peptid
unrel
tt
antigen
clarifi
role
tfk
hbenvag
uptak
cell
test
effect
solubl
tf
specif
lysi
present
ebvb
cell
incub
apc
tf
h
antigen
puls
result
drastic
inhibit
specif
lysi
control
experi
tf
block
specif
lysi
ttpuls
ebvb
cell
ttspecif
line
fig
contain
region
identifi
viral
envelop
sequenc
relev
virust
cell
interact
test
abil
ebvb
ceil
present
differ
hbv
envelop
antigen
construct
clone
recogn
region
present
test
protein
use
effector
ebvb
cell
present
hbenvag
prepar
test
effici
cell
present
entir
recombin
nativ
r
protein
high
effici
fig
present
lesser
degre
r
l
protein
r
protein
experi
perform
sever
time
equival
result
ctlmediat
lysi
induc
nonspecif
bystand
lysi
studi
antigenspecif
clone
kill
cell
present
hbenvag
examin
whether
kill
contactdepend
mechan
aspecif
product
solubl
factor
bystand
lysi
experi
perform
unlabel
cold
hbenvagpuls
target
cell
mix
slcrlabel
hot
unpuls
cell
class
iirestrict
ctl
lyse
bystand
target
tabl
contrast
puls
cell
ad
hot
target
cold
unpuls
cell
strong
lysi
former
observ
thu
suggest
kill
direct
cellt
cell
contact
induc
bystand
lysi
hbenvag
experi
perform
evalu
possibl
presenc
high
affin
membran
receptor
hbenvag
cell
thu
cell
incub
presenc
fix
amount
l
construct
increas
amount
cold
hbenvag
zgml
scatchard
plot
bind
data
show
cell
possess
high
affin
receptor
hbenvag
kd
x
fig
bind
lzsihbenv
l
ag
cell
inhibit
excess
concentr
cold
hbenv
con
struct
nativ
hbenvag
l
r
form
contain
protein
data
shown
furthermor
use
mihbenvag
level
nonspecif
bind
ie
bind
observ
cell
incub
label
antigen
larg
excess
cold
antigen
high
correspond
total
bind
inhibitor
solubl
tf
g
ml
bind
hbenvag
cell
inhibit
mab
tfr
experi
perform
evalu
whether
abl
interact
tfk
cell
incub
panel
mab
human
tfr
wash
remov
excess
unbound
mab
incub
min
presenc
nsihbenvag
experi
show
cell
mab
produc
strong
inhibit
nsihbenvag
bind
wherea
mab
induc
slight
inhibitori
effect
b
ebvb
cell
mab
elicit
mark
inhibit
hbenvag
bind
wherea
moder
decreas
hbenvag
bind
observ
remain
mab
fig
although
antitfr
mab
littl
effect
bind
inhibit
experi
perform
downregul
surfac
tfk
incub
subsequ
decreas
tsitf
nsihbenvag
bind
preincub
cell
bind
tf
hbenvag
decreas
respect
bind
tf
receptor
partial
inhibit
hbenvag
competit
bind
experi
carri
directli
evalu
abil
hbenvag
interact
tfr
recombin
hbenvag
l
construct
compet
radiolabel
tf
tfr
bind
site
ebvb
cell
though
significantli
lesser
extent
tf
fig
interestingli
rhbenvag
l
construct
exhibit
greater
capac
inhibit
bind
label
tf
lymphocyt
compar
ebvb
ceu
mgml
hbenvag
l
construct
requir
inhibit
label
tf
bind
ebvb
cell
respect
find
may
explain
ceil
present
hbenvag
effici
ebvb
lymphocyt
addit
studi
use
differ
hbenvag
construct
provid
result
line
obtain
capac
cell
present
differ
form
hbenvag
inde
entir
nativ
hbenvag
r
protein
abl
inhibit
tf
bind
tfr
higher
degre
rhbenvag
l
protein
alon
signific
effect
fig
human
activ
lymphocyt
express
class
ii
mhc
molecul
usual
fail
function
apc
present
solubl
antigen
sinc
cell
abl
present
denatur
antigen
peptid
hypothes
defect
level
antigen
process
altern
level
antigen
intern
due
inabl
cell
take
antigen
aspecif
last
possibl
recent
support
studi
indic
cell
unabl
present
convent
antigen
intern
process
present
antigen
bind
membran
receptor
high
effici
studi
show
cell
need
receptormedi
interact
antigen
effect
captur
present
light
result
evalu
whether
system
antigen
present
cell
could
use
identifi
receptor
use
lymphocytotrop
virus
enter
cell
particular
possibl
consid
hbv
demonstr
infect
lymphocyt
captur
cell
via
receptormedi
mechan
subsequ
process
present
specif
lymphocyt
studi
demonstr
clone
effici
present
hbenvag
process
endosom
compart
present
inhibit
chloroquin
find
hbenvag
present
drastic
inhibit
present
cell
coldpuls
argu
possibl
denatur
hbenvag
fragment
directli
bind
mhc
molecul
without
process
indic
intern
process
requir
result
suggest
hbenvag
use
surfac
receptor
enter
cell
investig
support
hypothesi
tfr
repres
one
membran
molecul
play
fundament
role
hbenvag
intern
present
inde
oktg
larg
seri
randomli
select
mab
abl
inhibit
kill
cell
specif
class
iirestrict
ctl
ad
antigen
puls
suggest
mab
block
hbenvag
captur
cell
also
inhibit
antigen
uptak
ebvb
cell
lesser
degre
observ
cell
therebi
suggest
hbenvag
may
part
use
receptor
enter
b
lymphocyt
howev
b
lymphocyt
may
also
captur
hbenvag
either
aspecificauy
interact
membran
structur
antitfr
mab
select
interf
hbenvag
uptak
apc
sinc
inhibit
present
either
peptid
need
process
unrel
tt
antigen
convers
aspecif
interact
apc
cell
rather
initi
hbenvag
uptak
inhibit
adhes
molecul
mab
indiscrimin
inhibit
specif
lysi
ad
antigen
puls
apc
mab
also
block
present
peptid
unrel
tt
antigen
select
block
specif
lysi
observ
puls
present
ebvb
cell
hbenvag
treatment
solubl
tf
suggest
tfkhbenvag
interact
crucial
initi
step
requir
antigen
process
present
endocytosi
recycl
tfk
either
ligand
antitfk
mab
extens
analyz
lymphoid
nonlymphoid
cell
agreement
find
found
inhibit
tfbind
receptor
downregul
surfac
till
cell
incub
follow
decreas
iodin
tf
hbenvag
bind
confirm
mab
block
hbenvag
present
interf
intern
data
shown
involv
tfk
hbenvag
interact
lyrephocyt
also
support
bind
experi
regard
hbenvag
partial
inhibit
tf
bind
furthermor
among
mab
inhibit
bind
tf
receptor
one
mab
markedli
decreas
iodin
hbenvag
bind
cell
clearli
suggest
epitop
involv
interact
hbenvag
tf
receptor
similar
ident
involv
bind
tf
best
knowledg
first
studi
indic
tfr
may
involv
bind
ligand
differ
tf
evalu
whether
system
antigen
present
cell
could
also
use
identif
sequenc
relev
hbenvag
interact
cell
result
dearli
indic
sequenc
map
region
base
abil
cell
present
entir
protein
protein
contain
region
without
sspecif
clone
failur
present
protein
alon
clone
moreov
find
cell
present
r
l
protein
contain
sequenc
region
lesser
extent
r
contain
entir
suggest
hbenvag
epitop
bind
cell
overlap
peptid
compar
analysi
capac
differ
hbenvag
molecular
construct
inhibit
bind
provid
evid
strictli
line
result
deriv
antigenpresent
studi
ie
hbenvag
sequenc
interact
tfr
cell
contain
region
precis
map
epitop
may
use
design
innov
synthet
vaccin
studi
b
cell
recognit
epitop
suggest
peptid
particularli
crucial
viru
neutral
moreov
domain
well
region
propos
involv
attach
hbv
hepatocyt
cell
suscept
infect
hypothes
antigen
present
cell
play
role
immunoregul
system
antigenspecif
clone
kill
present
cell
may
particip
gener
immunosuppress
elimin
lymphocyt
particular
cell
express
class
ii
molecul
macrophag
activ
cell
could
suscept
lysi
hbenvag
present
class
iirestrict
ctl
vivo
relev
cytotox
activ
mediat
cell
controversi
find
cell
act
ctl
report
number
viral
infect
model
includ
hbv
measl
herp
coronaviru
hand
ctl
elicit
bystand
lysi
indic
kill
direct
targetctl
contact
mechan
aspecif
secret
solubl
cytotox
mediat
find
ctl
abl
lyse
ctl
clone
hlarestrict
manner
contrast
report
suggest
ctl
resist
selfmedi
lysi
studi
use
murin
ctl
instead
human
ctl
util
present
studi
thu
possibl
explain
discrep
experi
human
class
iirestrict
ctl
specif
hiv
indic
lysi
cell
repres
immunosuppress
mechan
analog
class
iirestrict
ctl
specif
hbenvag
lyse
hbenvagpres
cell
therebi
downregnl
cell
respons
pose
select
advantag
hbv
persist
conclus
data
indic
activ
cell
process
present
hbenvag
high
effici
importantli
hbenvag
uptak
via
tfp
seem
essenti
initi
step
present
antigen
human
tfr
express
varieti
cell
type
includ
hepatocyt
repres
privileg
target
cell
hbv
infect
wide
tfp
distribut
may
thu
explain
broad
tissu
tropism
hbv
pathogen
enter
cell
use
bind
site
known
physiolog
ligand
eg
hiv
use
receptor
rhinovirus
enter
molecul
herp
simplex
viru
fibroblast
growth
factor
receptor
pneumocysti
carinii
mannos
receptor
identif
receptor
use
hbv
enter
cell
hbenvag
epitop
relev
interact
may
fundament
implic
design
altern
vaccin
also
therapeut
approach
chronic
hbv
infect
